Immuneoncia Therapeutics
- Company typePrivate
- Founded2016
- HeadquartersSeongnam, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Immuneoncia Therapeutics firmographics
Firmographics- Name
- Immuneoncia Therapeutics
- Legal name
- ImmuneOncia Therapeutics, Inc.
- Website
- https://immuneoncia.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Immuneoncia Therapeutics industry classification
Industry- Product category
- Immuno-Oncology Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Immuneoncia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Seongnam
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Immuneoncia Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Revenue model
- Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Immuneoncia's primary revenue model is through the development and eventual commercialization of immune-oncology drugs. The company is pursuing early approval pathways in rare cancer indications (NKT cell lymphoma) to enable faster commercialization, with plans for global licensing and overseas market entry. The company listed on KOSDAQ in May 2025, providing access to public capital markets.
- Technology Licensing/Transfer: Immuneoncia has out-licensed IMC-002 technology to 3DMedicines (signed in 2021), generating upfront and potential milestone/royalty payments.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Immuneoncia Therapeutics product offering
Product offeringCore offering
Immuneoncia Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of immuno-oncology antibody therapeutics, including a PD-L1 checkpoint inhibitor (IMC-001/Danburstotug), a next-generation CD47 antibody with reduced hematological toxicity (IMC-002), and a CD47xPD-L1 bispecific antibody (IMC-201). The company targets rare cancer indications such as NK/T-cell lymphoma for early regulatory approval in Korea and pursues global licensing deals with international pharmaceutical partners for broader market entry.
Product overview
Immuneoncia Therapeutics is a clinical-stage biopharmaceutical company specializing in immuno-oncology drug development. The company is developing a pipeline of three monoclonal antibody candidates: IMC-001 (Danburstotug), a PD-L1 inhibitor for NK/T-cell lymphoma; IMC-002, a next-generation CD47 inhibitor with minimized hematologic toxicity; and IMC-201, a bispecific antibody targeting both CD47 and PD-L1 simultaneously. The company utilizes its NTIG Platform technology for bispecific antibody development. Immuneoncia aims to bring Korea's first immuno-oncology drug to market, with a target of first commercialization by 2030.
Differentiator
Problem solved
Functional benefit
Products and services
- IMC-001 (Danburstotug) IMC-001 (Danburstotug) is a fully human monoclonal antibody designed as an immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1). It is in late-stage clinical development for treating relapsed/refractory NK/T-cell lymphoma and is manufactured in collaboration with Lonza for late-stage clinical supply and potential commercialization.
- IMC-002 IMC-002 is a next-generation fully human anti-CD47 monoclonal antibody designed to minimize red blood cell binding while maximizing selective binding to cancer cells, restoring innate immune response (macrophage phagocytosis) against tumors. Phase 1a/1b trials have demonstrated acceptable safety and signs of clinical benefit, particularly in refractory hepatocellular carcinoma and triple-negative breast cancer (TNBC) patients who failed standard therapies.
- IMC-201 IMC-201 is a bispecific antibody simultaneously targeting both CD47 and PD-L1, developed using Immuneoncia's NTIG® platform technology (licensed from ProGen in February 2023). It represents the next-generation immuno-oncology pipeline targeting multiple immune checkpoint pathways.
Quantifiable outcome
- IMC-002 showed acceptable safety profile in Phase 1a dose-escalation study (doses 5-30 mg/kg every 2-3 weeks) in patients with advanced or metastatic solid cancers who failed standard therapies.
- +3 more outcomes
Companies that use Immuneoncia Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles3 records
Immuneoncia Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Immuneoncia Therapeutics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- LonzacoreImmuneOncia Therapeutics and Lonza signed a manufacturing agreement in March 2026 for late-stage clinical supply of Danburstotug (IMC-001, a PD-L1 antibody). Lonza provides integrated end-to-end drug substance and drug product development and manufacturing. Drug substance is manufactured at Lonza's Slough (UK) site, and drug product development and clinical manufacturing are provided at Basel and Stein (CH) sites. This collaboration supports late-stage clinical development and potential commercialization of Danburstotug, targeting the rare cancer indication NKT cell lymphoma for early approval.
- WiBiologicsminorBispecific antibody co-development agreement signed in January 2024 with WiBiologics for joint development of bispecific antibody candidates.
- NuclixBiominormRNA formulation joint development agreement signed in August 2023 with NuclixBio, focusing on mRNA-based therapeutics development.
- ProGencoreNTIG® Platform technology introduction from ProGen in February 2023. This bispecific antibody platform technology enables the development of IMC-201, a CD47xPD-L1 bispecific antibody.
- LunitminorAI-based biomarker discovery joint research agreement signed in January 2024, focused on biomarker identification using artificial intelligence technologies.
- 3DMedicinescoreTechnology transfer agreement signed in 2021 for IMC-002 (anti-CD47 antibody) with 3DMedicines, enabling out-licensing of the technology for development and commercialization.
- RecochembiominorAIC (Antibody-Immune checkpoint) joint development agreement signed in November 2020 for collaborative development of immune checkpoint antibody candidates.
Scale indicators5 records
Recent moves7 records
Expansion highlights7 records
Immuneoncia Therapeutics competitors and assessment
Company assessmentDirect peers
- 3DMedicines: Chinese immuno-oncology company that licensed IMC-002 from Immuneoncia in 2021. Direct licensee and developer of the same CD47-targeting antibody in the China market, making it the closest peer by asset and geography.
- MacroGenics: US-based clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including CD47-targeting and bispecific antibody programs (e.g., enoblituzumab, MGD024). Closely comparable in immuno-oncology antibody pipeline composition and clinical-stage profile.
- Trillium Therapeutics (Pfizer): Canadian CD47-focused biopharmaceutical company acquired by Pfizer in 2022 (formerly NASDAQ: TRIL). Direct CD47 peer that validates the immuno-oncology space and illustrates large-pharma appetite for differentiated CD47 assets.
Regional players
- Genexine: Korean clinical-stage biopharmaceutical company developing antibody and immuno-oncology therapeutics, headquartered in the same Seoul innovation park (ProGen Bio Innovation Park) where Immuneoncia's R&D Center operates. Comparable Korean clinical-stage antibody developer.
Broad incumbents
- Akeso: Chinese biopharmaceutical company with a leading PD-1xVEGF bispecific antibody (cadonilimab/summetilimab) already approved. Directly comparable to Immuneoncia in pursuing next-generation bispecific immuno-oncology antibodies, with greater clinical and commercial scale.
- Innovent Biologics: Major Chinese biopharmaceutical company with approved PD-1 inhibitor sintilimab and an extensive oncology pipeline. Comparable in immuno-oncology antibody focus and Asia-centric commercialization model, with broader commercial reach.
- BeiGene: Global oncology-focused biopharmaceutical company with approved PD-1 inhibitor tislelizumab and broad hematology/oncology pipeline. Comparable in PD-1/PD-L1 checkpoint inhibitor development and global commercialization strategy, with significantly greater scale.
- Junshi Biosciences: Chinese biopharmaceutical company that developed toripalimab, an approved PD-1 inhibitor, and is advancing next-generation immuno-oncology antibodies including bispecifics. Comparable in oncology antibody development pipeline depth.
Others
- Yuhan Corporation: Major Korean pharmaceutical company and lead investor in Immuneoncia's Series B (2021) and Series C (2023) rounds. Strategic investor and joint development partner, comparable as a Korean pharma stakeholder evaluating immuno-oncology assets.
- Lunit: Korean AI-based biomarker discovery company that signed a joint research agreement with Immuneoncia in January 2024 for AI biomarker identification. Ecosystem participant enabling companion diagnostic and patient stratification strategies for immuno-oncology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Immuneoncia Therapeutics social profiles
Digital presenceImmuneoncia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immuneoncia Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
Immuneoncia Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immuneoncia Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immuneoncia Therapeutics
What does Immuneoncia Therapeutics do?
Immuneoncia Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of immuno-oncology antibody therapeutics, including a PD-L1 checkpoint inhibitor (IMC-001/Danburstotug), a next-generation CD47 antibody with reduced hematological toxicity (IMC-002), and a CD47xPD-L1 bispecific antibody (IMC-201). The company targets rare cancer indications such as NK/T-cell lymphoma for early regulatory approval in Korea and pursues global licensing deals with international pharmaceutical partners for broader market entry.
Is Immuneoncia Therapeutics a public or private company?
Immuneoncia Therapeutics is a private company. It is classified as public and is currently ipo.
When was Immuneoncia Therapeutics founded?
Immuneoncia Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Immuneoncia Therapeutics based?
Immuneoncia Therapeutics is headquartered in Seongnam, South Korea, in the Asia region.
How does Immuneoncia Therapeutics make money?
Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are technology Licensing/Transfer.
Who are Immuneoncia Therapeutics's main competitors?
Direct peers on record are 3DMedicines, MacroGenics and Trillium Therapeutics (Pfizer). Genexine is listed as a regional player. Broad incumbents are Akeso, Innovent Biologics, BeiGene and Junshi Biosciences. Others are Yuhan Corporation and Lunit.
Does Immuneoncia Therapeutics have an API?
No public API is recorded for Immuneoncia Therapeutics.
What industry is Immuneoncia Therapeutics in?
Immuneoncia Therapeutics's product category is Immuno-Oncology Antibody Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.